RT Journal Article
SR Electronic
T1 Genome-wide Discovery for Diabetes-Dependent Triglycerides-Associated Loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.06.22268848
DO 10.1101/2022.01.06.22268848
A1 Selvaraj, Margaret Sunitha
A1 Paruchuri, Kaavya
A1 Haidermota, Sara
A1 Bernardo, Rachel
A1 Rich, Stephen S.
A1 Peloso, Gina M.
A1 Natarajan, Pradeep
YR 2022
UL http://medrxiv.org/content/early/2022/03/08/2022.01.06.22268848.abstract
AB We aimed to discover loci associated with triglyceride (TG) levels in the context of type 2 diabetes (T2D). We conducted a genome-wide association study (GWAS) in 424,120 genotyped participants of the UK Biobank (UKB) with T2D status and TG levels. We stratified the cohort based on T2D status and conducted association analyses of TG levels for genetic variants with minor allele count (MAC) at least 20 in each stratum. Effect differences of genetic variants by T2D status were determined by Cochran’s Q-test and we validated the significantly associated variants in the Mass General Brigham Biobank (MGBB). Among 21,176 T2D and 402,944 non-T2D samples from UKB, stratified GWAS identified 19 and 315 genomic risk loci significantly associated with TG levels, respectively. Only chr6p21.32 exhibited genome-wide significant heterogeneity (I2=98.4%; pheterogeneity=2.1×10−15), with log(TG) effect estimates of -0.066 (95%CI: - 0.082, -0.050) and 0.002 (95%CI: -0.002, 0.006) for T2D and non-T2D, respectively. The lead variant rs9274619:A (allele frequency 0.095) is located 2Kb upstream of the HLA-DQB1 gene. We replicated this finding among 25,137 participants (6,951 T2D cases) of MGBB (pheterogeneity=9.5×10−3). Phenome-wide interaction association analyses showed that the lead variant was strongly associated with a concomitant diagnosis of type 1 diabetes (T1D) as well as diabetes-associated complications. In conclusion, we identified an intergenic variant near HLA-DQB1 significantly associates with decreased triglycerides only among those with T2D and highlights an immune overlap with T1D.Competing Interest StatementP.N. reports grants from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech / Roche, Novartis, and TenSixteen Bio, equity in geneXwell, and TenSixteen Bio, co-founder of TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work.Funding StatementP.N. is supported by grants from the National Institutes of Health (R01HL142711, R01HL148050, R01HL151283, R01HL127564, R01HL148565, R01HL151152, R01DK125782), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Fireman Chair). GMP is supported by NIH grants R01HL127564 and R01HL142711.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Secondary use of the data was approved by the Massachusetts General Hospital Institutional Review Board (protocol 2021P002228) and was facilitated through UKB application 7089. Secondary use of the data was approved by the Massachusetts General Hospital Institutional Review Board (protocol 2020P000904).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors